Mathew Shanley

Tumor response rates after initial treatment with peptide receptor radionuclide therapy have proven clinical benefit; however, complete response is uncommon.

Encouraging results are being seen following the administration of cabozantinib (Cabometyx) in patients with carcinoid and pancreatic neuroendocrine tumors. Clinical benefit of the drug has been exhibited in patients enrolled in a prospective phase II trial, which was initiated in July 2012; however, a randomized phase III trial will be necessary for confirmation.